Rehabilitative rheumatology: In recent years, new types of implants and advances in minimally invasive surgical techniques have been developed; these have implications for preoperative, postoperative, and rehabilitative care for patients with rheumatic disease. This study group, coordinated by Geri Neuberger, RN, MN, EdD, professor of nursing at the University of Kansas School of Nursing in Kansas City, will provide a forum for discussion of new surgical procedures for knee or hip replacement and implications for pre-operative and postoperative care, including optimal rehabilitation. The four presenters are: Stuart B. Goodman, MD, PhD, professor of surgery at Stanford University (Calif.); Matthew Liang, MD, professor in the department of health policy and management at Brigham and Women’s Hospital in Boston, Mass.; Marie Westby, BSc (PT), physical therapy teaching supervisor at Mary Pack Arthritis Program at the Vancouver Coastal Health in Vancouver, Canada; and Howard Hillstrom, PhD, director of the Leon Root, MD, Motion Analysis Lab at the Hospital for Special Surgery in New York City.
APS: APS is an evolving field with significant new knowledge in the clinical arena, as well as in the basic sciences and pathogenesis area. This year’s study group coordinator, Silvia S. Pierangeli, MD, professor of rheumatology at the University of Texas Medical Branch in League City, has planned a program that will provide balanced coverage of the most recent advances and discoveries regarding the treatment of APS. E. Nigel Harris, MD, vice-chancellor of the University of the West Indies in Kingston, Jamaica, will present challenging clinical and diagnostics cases within an interactive session. Ricard Cervera, MD, head of the department of autoimmune diseases at the Hospital Clinic and Universitat de Barcelona in Spain, will take a look at catastrophic APS. Jacob Rand, MD, professor of pathology at Montefiore Medical Center in Bronx, N.Y., will discuss a new mechanistic assay for the detection of antiphospholipid antibodies and will present new findings on the effects of hydroxychloroquine therapy in the treatment of APS. Finally, Dr. Pierangeli will give an update on pathogenic mechanism mediated by antiphospholipid antibodies and new targeted therapies in APS.
Tuesday, October 28, 12:45–2:15 p.m.
Metabolic bone disease: Ellen Field, MD, a rheumatologist in private practice in Bethlehem, Pa., with special interest and experience in osteoporosis and clinical research, is the coordinator of this year’s study group, which will focus on the role that biologics play in the treatment of metabolic bone disease. Biologics are becoming a standard of care in multiple diseases, including inflammatory arthropathy, psoriasis, and inflammatory bowel disease. During this year’s group, Willem Lems, MD, of the Free University Hospital in Amsterdam, The Netherlands, and Nancy E. Lane, MD, of the University of California, Davis—both of whom are international experts in the field of metabolic bone disease—will address the clinical and basic science effects of using biologics to treat the disease.
